Stay updated with breaking news from Zymeworks Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Opportunistic proposal from activist shareholder substantially undervalues Zymeworks and is not in the best interests of shareholders Shareholders are right to question the motive behind an... | May 20, 2022
Press release content from PR Newswire. The AP news staff was not involved in its creation.
(Reuters) - Investment firm All Blue Capital would be advised by Alan Barge, former oncology head at British drugmaker AstraZeneca Plc, in its bid to ...
/PRNewswire/ -- All Blue Capital ("AB"), a global investment firm, today announced that biopharmaceutical industry leader and expert, Alan Barge, MD, has...
/PRNewswire/ -- All Blue Capital ("AB"), a global investment firm, today announced that biopharmaceutical industry leader and expert, Alan Barge, MD, has...